Merck's Leadership Position In Immuno Oncology Is Improving By: Benzinga via Benzinga January 12, 2017 at 09:06 AM EST Merck & Co., Inc. (NYSE: MRK) unexpectedly announced a priority review for Keytruda plus chemo in first-line lung cancer. This, ... Read More >> Related Stocks: Merck & Co